EGFR-TKIs have markedly transformed the therapeutic paradigm for patients with EGFR-mutated NSCLC (EGFRm NSCLC) due to their high specificity and relatively favorable toxicity profile. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.